Skip to content

China National Cancer Early Screening Trial: Lung and Colorectal Cancer

China National Cancer Early Screening Trial: Lung and Colorectal Cancer - CHANCES

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025257
Enrollment
Unknown
Registered
2019-08-18
Start date
2019-08-20
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung and colorectal cancer

Interventions

Group A:Annual LDCT (5 rounds) and colonoscopy for any year (first year is recommended)
Group B:Biennial LDCT (3 rounds) and annual FIT (5 rounds), those who have FIT positive results will undertake colonoscopy
Group C:To inform the participants of high risk of lung cancer and recommend them to undertake lung cancer screening in other regular medical institutions
To recommend colonoscopy for any year (first year is recommended), and those who are unwilling to undertake colonoscopy will receive FIT screening (5 rounds), those

Sponsors

National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50~74 years old; 2. Permanent residents of the city where the screening site located (length of residency=5 years); 3. Citizen with full legal capacity for civil capacity; 4. Have any one of the following risk factors: (1) Smoking history>=30 pack-years with a subsequent smoking cessation =5 years (asbestos, radon, beryllium, uranium, chromium, cadmium, nickel, silicon, diesel exhaust, soot and soot ash); (4) Non-smoking women: second hand smoking from family members who live together or coworkers in the same room with a smoking history >=30 pack-years with a subsequent smoking cessation = 20 years; 5. Willing to comply with the research protocol: (1) Agree to sign informed consent before entering the research; (2) Willing to fill out Personal Information Record Form and Risk Factors and Contact Information Questionnaire; (3) Willing to provide biospecimens for detection and research, including (but not limited to) blood and feces; 6. The tuberculosis patients that have been cured for at least two years 7. Willing to finish long-term follow-up conducted by community health care personnel. Notes: Participants who participated in colorectal cancer screening after 5 years or lung cancer screening after 3 years were given priority in this study.

Exclusion criteria

Exclusion criteria: 1. Unable to complete the informed consent procedure due to any physical or mental illness; 2. The current physical condition is not acceptable for thoracic surgery or radiotherapy; 3. Metal implants or metal facilities on chest or back (heart stents, cardiac pacemakers, etc); 4. Unable to finish standard LDCT screeninh: (1) Unable to ensure respiratory function without oxygen supply; (2) Unable to raise arms over head while lying on back; 5. History of malignancy or have received cancer treatment before (excluding skin basal cell carcinoma and cervical carcinoma in situ); 6. Have been included in colonoscopy, fiber sigmoidoscopy, double contrast angiography, CT simulation colonoscopy in the last 5 years; 7. Have been included in chest CT scan in last 36 months; 8. Received surgical resection of lung tissue (including whole lung, lung lobe, sublobular lobe, lung segment and wedge shape, excluding lung puncture and lung biopsy); 9. Unexplained weight loss of 5 kilograms or more within the past 12 months or unexplained hemoptysis; 10. Suffering from certain life-threatening diseases, including severe cardiac-cerebral vascular diseases, heart failure, kidney failure, severe liver cirrhosis, etc; 11. Have been included in any other lung screening programs in the last 5 years and/or colorectal cancer screening programs in the last 3 years.

Design outcomes

Primary

MeasureTime frame
lung cancer mortality;

Secondary

MeasureTime frame
colorectal cancer mortality;stage shift;detection rate of lung nodules;detection rate of colorectal precancerous lesions;detection rate of lung cancer;detection rate of colorectal cancer;proportion of stage I cases;all-cause mortality;

Countries

China

Contacts

Public ContactJie He

National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

nli@cicams.ac.cn+86 10 8944 5007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026